Video

Dr Cynthia Delgado Outlines How Frailty Affects Outcomes in Patients Receiving Hemodialysis

Frailty significantly raises the risk of developing disabilities as a result of hemodialysis, so even patients who are intermediately frail should be monitored, said Cynthia Delgado, MD, associate professor of medicine at the San Francisco Veterans Affairs Medical Center and University of California San Francisco Medical Center.

Frailty significantly raises the risk of developing disabilities as a result of hemodialysis, so even patients who are intermediately frail should be monitored, said Cynthia Delgado, MD, associate professor of medicine at the San Francisco Veterans Affairs Medical Center and University of California San Francisco Medical Center.

Transcript

How does frailty affect outcomes in patients receiving hemodialysis?

Well, I’ve done quite a bit of work in frailty, and I will say that I consider frail patients the most vulnerable of all our patient populations, they’re at highest risk of developing disabilities and progressive issues with those disabilities. And so for me, they represent a vulnerable patient population, and we should be targeting even individuals who are intermediately frail, because I think that, based on some of the studies I’ve done and a cohort study that I actually just finished running, where I found that even individuals who were intermediate frail, were also at significant risk of issues.

Related Videos
Picture of San Diego skyline with words ASH Annual Meeting 2024 and health icons overlaid on the bottom
Screenshot of an interview with Amir Ali, PharmD, BCOP
Mansi Shah, MD, assistant professor, Rutgers Cancer Institute of New Jersey
 Alvaro Alencar, MD, associate professor of clinical medicine, chief medical officer, University of Miami Sylvester Comprehensive Cancer Center
Dr Cesar Davila-Chapa
Screenshot of an interview with Nadine Barrett, PhD
Milind Desai, MD
Masanori Aikawa, MD
Neil Goldfarb, GPBCH
Mabel Mardones, MD.
Related Content
AJMC Managed Markets Network Logo
CH LogoCenter for Biosimilars Logo